Compare SOAR & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOAR | LYRA |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.6M |
| IPO Year | N/A | 2020 |
| Metric | SOAR | LYRA |
|---|---|---|
| Price | $0.47 | $1.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 5.4M | 147.6K |
| Earning Date | 03-30-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $58,312,000.00 | $600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $1.51 |
| 52 Week High | $6.48 | $37.50 |
| Indicator | SOAR | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 31.57 |
| Support Level | $0.42 | $1.73 |
| Resistance Level | $0.51 | $2.05 |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 8.95 | 3.87 |
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.